Showing 1341-1350 of 1477 results for "".
- BVI Announces Certification for its IOL Portfolio Under the European Medical Device Regulationhttps://modernod.com/news/bvi-announces-certification-for-its-iol-portfolio-under-the-european-medical-device-regulation/2481094/BVI announced certification for its IOL portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medica
- New MaximEyes.com Software Designed to Simplify EHR Navigation and Patient Flowhttps://modernod.com/news/new-maximeyescom-software-designed-to-simplify-ehr-navigation-and-patient-flow/2481076/First Insight has introduced MaximEyes.com, which is desinged go allow eye care processionals to access data—anywhere, anytime, from any device—in a web browser or via a local server.
- NIH Researchers Develop Gene Therapy for Rare Ciliopathyhttps://modernod.com/news/nih-researchers-develop-gene-therapy-for-rare-ciliopathy/2481074/Researchers from the National Eye Institute (NEI) have developed a gene therapy that rescues cilia defects in retinal cells affected by a type of Leber congenital amaurosis (LCA), a disease that causes blindness in early childhood. Using patient-derived retina organoids (also known as retinas-in-
- iOR Partners Appoints Health Care Industry Veteran James R. Williams as New President and CEOhttps://modernod.com/news/ior-partners-welcomes-health-care-industry-veteran-as-new-president-and-ceo/2481068/iOR Partners announced that James R. Williams has been appointed to serve as the company’s new President and CEO. Mr. Williams joined iOR as Chief Operating Officer (COO) earlier this year and served on the iOR Board of Directors for 2 years. Mr. Williams brings over 30
- Bausch + Lomb Named Exclusive Global Distributor of Alfa Instruments Intraocular Dyeshttps://modernod.com/news/bausch-lomb-named-exclusive-global-distributor-of-alfa-instruments-intraocular-dyes/2481060/Bausch + Lomb and Alfa Instruments announced that the companies have entered into an exclusive distribution agreement under which Bausch + Lomb will distribute and commercialize Alfa Instruments' line of surgical intraocular dyes—Vitreocare—globally with the exception of Italy, wh
- Bausch + Lomb Announces Strategic Partnership With Munich Surgical Imaging GmbHhttps://modernod.com/news/bausch-lomb-announces-strategic-partnership-with-munich-surgical-imaging-gmbh-1/2481053/Bausch + Lomb announced its strategic partnership with Munich Surgical Imaging GmbH (MSI)—a wholly‐owned subsidiary of Heidelberg Engineering GmbH. Based in Munich, Germany, MSI develops state‐of‐the art digital visualization and image‐guided surgical applications. The new MSI platform, dev
- Alcon to Acquire Aerie Pharmaceuticalshttps://modernod.com/news/alcon-to-acquire-aerie-pharmaceuticals/2481041/In another move to bolster its glaucoma portolio and expand its pharmaceutical offerings, Alcon announced it is acquiring Aerie Pharmaceuticals for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s lastest closing price. The transaction was a
- Research to Prevent Blindness and the American Academy of Ophthalmology Award New Research Grants to Improve Eye Carehttps://modernod.com/news/research-to-prevent-blindness-and-the-american-academy-of-ophthalmology-award-new-research-grants-to-improve-eye-care/2481025/The American Academy of Ophthalmology and Research to Prevent Blindness (RPB) announced the 2022 recipients of the RPB/AAO Award for IRIS Registry Research. The researchers will use the IRIS Registry—the nation’s first and largest comprehensive eye disease clinical registry—to c
- OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-therapeutics-announces-first-patient-dosed-in-ott166-phase-2-dream-clinical-trial-for-diabetic-retinopathy/2481009/OcuTerra Therapeutics announced that the first patient was dosed in its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating OTT166 in adult patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) or mild proli
- LumiThera Purchases MacuLogix Assetshttps://modernod.com/news/lumithera-purchases-maculogix-assets/2481007/LumiThera announced the purchase of the assets of MacuLogix. Terms of the deal were not disclosed. MacuLogix is the developer of the wearable AdaptDX Pro dark adaptometer, which allows eye care professionals to measure dark adaptation—designed to dia